Excluded in this study were patients who were prescribed with docetaxel or interacting drugs before the initial diagnosis of breast cancer, patients with hematologic malignancy, or patients who were prescribed with G-CSF before the first docetaxel prescription. This evidence concerns the gene CSF3 and breast cancer.